Prestige Biologics has participated in the BIOPLUS-INTERPHEX KOREA 2022 which was held from August 3 to 5 at COEX, Seoul, Korea.BIOPLUS-INTERPHEX KOREA 2022 is a bio-pharmaceutical exhibition that encompasses biopharmaceutical Value Chain and proposes ways to expand overseas by building global business networks. In this year's event, around 200 companies from 15 countries participated and 350 booths were open.At the booth, Prestige Biologics attracted the eyes of participants and visitors with its distinctive CDEMO service which is a concept to add Engineering to the existing CDMO service, providing customized solutions for biomanufacturing process. In addition, many visitors showed interest in Prestige Biologics' proprietary technologies and facilities, particularly the 'ALITA Smart BioFactoryFM' and 'Single-Use System'.During the event, Prestige Biologics put various efforts to raise profile such as conducting surveys and giving free gifts. The company also discussed collaborations and partnerships with various global biopharmaceutical companies.

In line with the new government’s plan to nurture Korea’s Bio-health industry, Prestige Biologics is devoting itself to expanding business and stepping up as a global CDMO. On July 27, the government announced an industrial innovation plan that includes providing more support for the development of local COVID-19 vaccines and treatments, ways to increase private investment, and the easing of unnecessary regulations. Earlier, Prestige Biologics has announced that it will invest KRW 169.9 billion in vaccine and biologics manufacturing facilities by 2023. With its global scale biomanufacturing facilities that boast a total production capacity of 154,000L, the company is advancing to the global CDMO market. In addition, Prestige Biologics is also reinforcing its vaccine business with Plant 3 (Voyager) which is a manufacturing facility dedicated to vaccines with 88,000L capacity. Prestige Biologics has gained recognition for its state-of-the-art facilities and proprietary technology. The company has acquired four biomanufacturing-related patents this year alone and won the Best CDMO Award in ‘Korea Bioprocessing Excellence Award 2022’ last June. Currently Prestige Biologics is focusing on securing new clients and contracts by participating in international exhibitions and establishing a new division dedicated to business development.

Topic : Biopharmaceutical Manufacturing from Clinical to Commercial Stage by Single Use System- Event : 11th Biologics Manufacturing Korea- Conference : Enhancing Korea's Vein-to-Vein Supply Chain Management with the Right Technology, Governance and Strategies - Presentation Date : June 29, 2022​- Venue : Songdo Convensia, Incheon, Korea

Prestige Biologics (CEO Yang Jae-young), specializing in biopharmaceutical CDMO, has won the Best CDMO Award at the Korea Bioprocessing Excellence Awards 2022, which was held on June 29 at the Songdo Convention Center in Incheon, South Korea.The Korea Bioprocessing Excellence Awards, held by IMPAC, aims to recognize organizations within Korea that have engaged in substantial efforts to innovate, optimize processes, and uphold a high level of efficacy, quality, and safety in biological products manufacturing. With high reputation on its biomanufacturing facilities and technologies, Prestige Biologics has been recognized as the winner of the Best CDMO Award this year for contributing to reducing cost, improving speed, and enhancing quality in bioprocessing.